Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of AR106572A1publicationCriticalpatent/AR106572A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se describen proteínas de unión al antígeno que interactúan con ASGR, ASGR-1 y/o ASGR-2, así como métodos para producir y utilizar dichas proteínas de unión al antígeno. Métodos para tratar y prevenir la enfermedad cardiovascular mediante la administración de una cantidad farmacéuticamente eficaz de proteínas de unión al antígeno de ASGR, ASGR-1 y/o ASGR-2. Se describen métodos para tratar y prevenir la enfermedad cardiovascular mediante la administración de una cantidad farmacéuticamente eficaz de composiciones de ARN interferente que reducen la expresión de ASGR, ASGR-1 y/o ASGR-2.Antigen binding proteins that interact with ASGR, ASGR-1 and / or ASGR-2 are described, as well as methods for producing and using said antigen binding proteins. Methods for treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of antigen-binding proteins of ASGR, ASGR-1 and / or ASGR-2. Methods for treating and preventing cardiovascular disease are described by administering a pharmaceutically effective amount of interfering RNA compositions that reduce the expression of ASGR, ASGR-1 and / or ASGR-2.